PCSK9
A liver enzyme that degrades LDL receptors — blocking it lowers LDL cholesterol sharply, and is now a target for gene-silencing therapies that may need only one or two doses.
PCSK9 is a protein the liver secretes to tag its own LDL receptors for destruction. Fewer receptors means more LDL stays in the blood. Blocking PCSK9 — by antibody, RNA silencing, or base editing — restores receptor levels and can cut LDL by 50–60 %. The clinical interest is durability: injectable antibodies need dosing every two weeks, but RNA and gene-editing approaches aim to silence or disable the gene once, turning a chronic prescription into a procedure. The hard part is delivery — getting the editing machinery into hepatocytes reliably and safely.
Where it came from
Related players
Finds citing this concept
Overall = breadth + depth + substance + ½·novelty
The fix was the wrapper
A single IV infusion made one permanent DNA edit in the liver and cut LDL cholesterol by up to 62% — but the new result is that swapping the delivery vehicle cleared the safety signal that halted the first attempt.